Evidence map›Paper›PMID 28692681›Full record

ArticlePloS one2017

Cervical HPV type-specific pre-vaccination prevalence and age distribution in Croatia.

Ivan Sabol, Nina Milutin Gašperov, Mihaela Matovina, Ksenija Božinović, Goran Grubišić, Ivan Fistonić, Dragan Belci, Laia Alemany, Sonja Džebro, Mara Dominis and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Ivan SabolDepartment of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia.
Nina Milutin GašperovDepartment of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia.ORCID http://orcid.org/0000-0002-6219-7836
Mihaela MatovinaDepartment of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia.
Ksenija BožinovićDepartment of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia.
Goran GrubišićUniversity Hospital Sisters of Mercy, Clinic of Obstetrics and Gynaecology, Zagreb, Croatia.
Ivan FistonićObstetrics, Gynecology and Menopause Clinic, Zagreb, Croatia.
Dragan BelciDepartment of Gynecology and Obstetrics, General Hospital Pula, Pula, Croatia.
Laia AlemanyCancer Epidemiology Research Program, Unit of Infections and Cancer, Catalan Institute of Oncology, Barcelona, Spain.
Sonja DžebroDepartment of Pathology and Cytology, University of Zagreb, School of Medicine, University Hospital Merkur, Zagreb, Croatia.
Mara DominisDepartment of Pathology and Cytology, University of Zagreb, School of Medicine, University Hospital Merkur, Zagreb, Croatia.
Mario ŠekerijaCroatian National Cancer Registry, Croatian Institute of Public Health, Zagreb, Croatia.
Sara TousCancer Epidemiology Research Program, Unit of Infections and Cancer, Catalan Institute of Oncology, Barcelona, Spain.
Silvia de SanjoséCancer Epidemiology Research Program, Unit of Infections and Cancer, Catalan Institute of Oncology, Barcelona, Spain.
Magdalena GrceDepartment of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia.
Ruđer Bošković Institute · HRInstitut Català d'Oncologia · ESUniversity of Zagreb · HRJuraj Dobrila University of Pula · HRSisters of Charity Hospital · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main etiological factor of precancerous lesion and invasive cervical cancer are oncogenic human papillomaviruses types (HPVs). The objective of this study was to establish the distribution of the most common HPVs in different cervical lesions and cancer prior to the implementation of organized population-based cervical screening and HPV vaccination in Croatia. In this study, 4,432 cervical specimens, collected through a 16-year period, were tested for the presence of HPV-DNA by polymerase chain reaction (PCR) with three sets of broad-spectrum primers and type-specific primers for most common low-risk (LR) types (HPV-6, 11) and the most common high-risk (HR) types (HPV-16, 18, 31, 33, 45, 52, 58). Additional 35 archival formalin-fixed, paraffin embedded tissue of cervical cancer specimens were analyzed using LiPA25 assay. The highest age-specific HPV-prevalence was in the group 18-24 years, which decreased continuously with age (P<0.0001) regardless of the cytological diagnosis. The prevalence of HR-HPV types significantly increased (P<0.0001) with the severity of cervical lesions. HPV-16 was the most common type found with a prevalence (with or without another HPV-type) of 6.9% in normal cytology, 15.5% in atypical squamous cells of undetermined significance, 14.4% in low-grade squamous intraepithelial lesions, 33.3% in high-grade squamous intraepithelial lesions, and 60.9% in cervical cancer specimens (P<0.0001). This study provides comprehensive and extensive data on the distribution of the most common HPV types among Croatian women, which will enable to predict and to monitor the impact of HPV-vaccination and to design effective screening strategies in Croatia.

Indexed as

VaccinationAdolescentAdultAgedAged, 80 and overAge DistributionCroatiaFemaleHumansIncidenceMiddle AgedPapillomaviridaePapillomavirus InfectionsPrevalenceUterine Cervical NeoplasmsYoung Adult

Identifiers

PMID28692681
PMCPMC5503252
OpenAlexW2735555822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.